No Data
SUNHO BIO-B: Annual Report 2024
Shenghe Biotechnology-B (02898) released its 2024 annual performance, reporting a net loss of 79.965 million yuan, a year-on-year reduction of 39.7%.
Shenghe Biotechnology-B (02898) released its performance for the year 2024, with Other income of 9.485 million yuan (RMB, down...
SUNHO BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
Shenghe Bio-B (02898.HK) plans to hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui March 19th丨Shenghe Biology-B (02898.HK) announced that the Board of Directors meeting will be held on March 31, 2025 (Monday) to consider and approve the group's performance for the year ending December 31, 2024, and its publication, as well as to handle any Other matters.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Shenghe Biology - B [02898] is currently reported at 3 Hong Kong dollars, a decline of 27.89%.
As of 15:21, Shenghe Bio-B [02898] is reported at 3 HKD, down 1.16 HKD or 27.89% from yesterday's closing price of 4.16 HKD, with a trading volume of 0.0018 million HKD. Today's highest price is 3 HKD, the lowest price is 3 HKD. Based on yesterday's closing price, the 10-day average is 3.89 HKD, the 50-day average is 4.27 HKD, and the current PE is -2.64 times, with a 14-day strength index of 70.42.